Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
CVS – Q1/2026 results beat expectations, guidance raised as recovery signals strengthen
📌 CVS Health delivered a stronger-than-expected Q1, with revenue reaching $100.4 billion, up 6.2% YoY and well above expectations of around $95 billion. Adjusted EPS came in at $2.57, beating the $2.21 forecast and showing clearer profit improvement than the market expected.
💡 The key point is that CVS raised its full-year 2026 outlook again. The company now expects adjusted EPS of $7.30–$7.50, revenue of at least $405 billion, and operating cash flow of at least $9.5 billion, reflecting stronger management confidence after Q1.
🔎 The main driver came from Aetna, where the medical cost ratio fell from 87.3% to 84.6%. This matters because elevated medical costs had been one of the biggest risks for CVS in previous quarters.
⚠️ Although the stock reacted positively after the report, the risk has not fully disappeared. Q2 will be the next key test to confirm whether CVS can sustain better medical cost control and keep its turnaround on track.
#StockMarketInsight